Background Many reports have estimated the prevalence of anti-hepatitis C virus (HCV) antibody among hemodialysis (HD) patients; however, the prevalence of HCV core antigenwhich indicates the presence of chronic HCV infectionis not known. HD patients. value less than 0.05 was considered statistically significant. All statistical analyses were performed using the SPSS software package (SPSS, Japan Inc., Version 14.0). RESULTS Canertinib Table ?Table1 shows1 shows sex- and age-specific prevalences of anti-HCV antibody in hemodialysis patients and population-based controls. Among population-based controls, the prevalence of anti-HCV antibody increased with advancing age; however, no such association was observed among hemodialysis patients. A sex difference in the prevalence of anti-HCV antibody was not found in the population-based controls; however, among the hemodialysis patients, the prevalence of anti-HCV antibody was higher in men than in women (12.5% vs 8.5%, < 0.05). Table 1. Sex- and age-specific prevalences of anti-HCV antibody in hemodialysis patients and a general populace The prevalence of anti-HCV antibody was considerably higher in hemodialysis patients than in controls. The SPR (95% CI) for anti-HCV antibody was 8.39 (6.72C10.1) in male hemodialysis patients and 5.42 (3.67C7.17) in female hemodialysis patients. Table ?Table2 shows2 shows sex- and age-specific prevalences of HCV core antigen in hemodialysis Canertinib patients and population-based controls. A Mouse monoclonal to alpha Actin positive association between the prevalence of HCV primary antigen and age group was within controls however, not in hemodialysis sufferers. The prevalence of HCV primary antigen was also higher in male hemodialysis sufferers than in feminine hemodialysis sufferers (7.8% vs 4.1%, < 0.05). The SPR (95% CI) for HCV primary antigen was 12.9 (9.66C16.1) in man hemodialysis sufferers and 8.77 (4.72C12.8) in feminine hemodialysis sufferers. Desk 2. Sex- and age-specific prevalences of HCV primary antigen in hemodialysis sufferers and normal handles Table ?Desk3 displays3 displays prevalences of anti-HCV HCV and antibody primary antigen by dialysis vintage. Male and feminine sufferers with much longer hemodialysis vintages (10C14 years or 15 years) acquired high prevalences of anti-HCV antibody than do male and feminine sufferers using a dialysis classic less than a decade (< 0.05). Man and female sufferers using a dialysis classic of 15 years or even more had incredibly high prevalences of anti-HCV antibody. Nevertheless, among the dialysis classic subgroups, male sufferers using a dialysis classic of 15 years or more had the highest prevalence of HCV core antigen. Table 3. Prevalences of anti-HCV antibody and HCV core antigen among hemodialysis individuals, stratified by hemodialysis vintage Both male and female individuals in the 4 organizations with the shortest dialysis vintage (ie, <10 years) experienced related prevalences of HCV antibody, no matter dialysis vintage (approximately 9% in male Canertinib hemodialysis individuals and 5% in female hemodialysis individuals in each of the 4 organizations). Table ?Table4 shows4 shows the odds ratios attributable to each element for having chronic HCV infection or past HCV infection. Male sex and dialysis vintage were individually associated with a higher prevalence of chronic HCV illness. The prevalence of chronic HCV illness among male hemodialysis individuals was double that of female individuals. However, only hemodialysis vintage was individually associated with an increased prevalence of past HCV illness. Table 4. Odds ratios for each risk element for past Canertinib or chronic HCV illness Conversation With this study, we analyzed the prevalences of HCV antibody and HCV core antigen in adult hemodialysis individuals. We estimated SPRs for both anti-HCV antibody and HCV core antigen among hemodialysis individuals, and compared these estimates to the people of the general population living in the same area. Individuals who are positive for HCV core antigen all have chronic HCV illness, whereas individuals with anti-HCV antibody consist of those people who have retrieved from HCV an infection, as.